Flavio Luis Dantas Portela
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Flavio Luis Dantas Portela has a total of 167 co-authors. Here are the top co-authors by number of shared publications:
Akira I Hida
Department of Pathology Matsuyama Shimin Hospital Matsuyama Japan
3 shared publicationsAlbrecht Stenzinger
Institute of Pathology, University Hospital Heidelberg, Centers for Personalized Medicine (ZPM) Heidelberg Germany
3 shared publicationsAmy Ly
Department of Pathology Massachusetts General Hospital Boston MA USA
3 shared publicationsAn Coosemans
Department of Oncology, Laboratory of Tumor Immunology and Immunotherapy KU Leuven Leuven Belgium
3 shared publicationsAnant Madabhushi
Department of Biomedical Engineering, Radiology and Imaging Sciences, Biomedical Informatics, Pathology Georgia Institute of Technology and Emory University Atlanta GA USA
3 shared publicationsAnikó Kovács
Department of Clinical Pathology Sahlgrenska University Hospital Gothenburg Sweden
3 shared publications
Latest Publications
- Open Access
- 17 January 2024
- Published by Wiley in The Journal of Pathology
- Vol. 262 (3) , 271-288
Image‐based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno‐oncology Biomarker Working Group on Breast Cancer
Recent advances in the field of immuno‐oncology have brought transformative changes in the management of cancer patients. The immune profile of tumours has been found to have key value in predicting disease prognosis and treatment response in various cancers. Multiplex immunohistochemistry and immunofluorescence have emerged as potent tools for the simultaneous detection of multiple protein biomarkers in a single tissue section, thereby expanding opportunities for molecular and immune profiling while preserving tissue samples. By establishing the phenotype of individual tumour cells when distributed within a mixed cell population, the identification of clinically relevant biomarkers with high‐throughput multiplex immunophenotyping of tumour samples has great potential to guide appropriate treatment choices. Moreover, the emergence of novel multi‐marker imaging approaches can now provide unprecedented insights into the tumour microenvironment, including the potential interplay between various cell types. However, there are significant challenges to widespread integration of these technologies in daily research and clinical practice. This review addresses the challenges and potential solutions within a structured framework of action from a regulatory and clinical trial perspective. New developments within the field of immunophenotyping using multiplexed tissue imaging platforms and associated digital pathology are also described, with a specific focus on translational implications across different subtypes of cancer. © 2024 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
- 17 January 2024
- Published by Wiley in The Journal of Pathology
- Vol. 262 (3) , 271-288
Open AccessImage‐based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno‐oncology Biomarker Working Group on Breast Cancer
Recent advances in the field of immuno‐oncology have brought transformative changes in the management of cancer patients. The immune profile of tumours has been found to have key value in predicting disease prognosis and treatment response in various cancers. Multiplex immunohistochemistry and immunofluorescence have emerged as potent tools for the simultaneous detection of multiple protein biomarkers in a single tissue section, thereby expanding opportunities for molecular and immune profiling while preserving tissue samples. By establishing the phenotype of individual tumour cells when distributed within a mixed cell population, the identification of clinically relevant biomarkers with high‐throughput multiplex immunophenotyping of tumour samples has great potential to guide appropriate treatment choices. Moreover, the emergence of novel multi‐marker imaging approaches can now provide unprecedented insights into the tumour microenvironment, including the potential interplay between various cell types. However, there are significant challenges to widespread integration of these technologies in daily research and clinical practice. This review addresses the challenges and potential solutions within a structured framework of action from a regulatory and clinical trial perspective. New developments within the field of immunophenotyping using multiplexed tissue imaging platforms and associated digital pathology are also described, with a specific focus on translational implications across different subtypes of cancer. © 2024 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
- 23 August 2023
- Published by Wiley in The Journal of Pathology
- Vol. 260 (5) , 514-532
Spatial analyses of immune cell infiltration in cancer: current methods and future directions: A report of the International Immuno‐Oncology Biomarker Working Group on Breast Cancer
Modern histologic imaging platforms coupled with machine learning methods have provided new opportunities to map the spatial distribution of immune cells in the tumor microenvironment. However, there exists no standardized method for describing or analyzing spatial immune cell data, and most reported spatial analyses are rudimentary. In this review, we provide an overview of two approaches for reporting and analyzing spatial data (raster versus vector‐based). We then provide a compendium of spatial immune cell metrics that have been reported in the literature, summarizing prognostic associations in the context of a variety of cancers. We conclude by discussing two well‐described clinical biomarkers, the breast cancer stromal tumor infiltrating lymphocytes score and the colon cancer Immunoscore, and describe investigative opportunities to improve clinical utility of these spatial biomarkers. © 2023 The Pathological Society of Great Britain and Ireland.
- 23 August 2023
- Published by Wiley in The Journal of Pathology
- Vol. 260 (5) , 514-532
Spatial analyses of immune cell infiltration in cancer: current methods and future directions: A report of the International Immuno‐Oncology Biomarker Working Group on Breast Cancer
Modern histologic imaging platforms coupled with machine learning methods have provided new opportunities to map the spatial distribution of immune cells in the tumor microenvironment. However, there exists no standardized method for describing or analyzing spatial immune cell data, and most reported spatial analyses are rudimentary. In this review, we provide an overview of two approaches for reporting and analyzing spatial data (raster versus vector‐based). We then provide a compendium of spatial immune cell metrics that have been reported in the literature, summarizing prognostic associations in the context of a variety of cancers. We conclude by discussing two well‐described clinical biomarkers, the breast cancer stromal tumor infiltrating lymphocytes score and the colon cancer Immunoscore, and describe investigative opportunities to improve clinical utility of these spatial biomarkers. © 2023 The Pathological Society of Great Britain and Ireland.
- Open Access
- 23 August 2023
- Published by Wiley in The Journal of Pathology
- Vol. 260 (5) , 498-513
Pitfalls in machine learning‐based assessment of tumor‐infiltrating lymphocytes in breast cancer: A report of the International Immuno‐Oncology Biomarker Working Group on Breast Cancer
The clinical significance of the tumor‐immune interaction in breast cancer is now established, and tumor‐infiltrating lymphocytes (TILs) have emerged as predictive and prognostic biomarkers for patients with triple‐negative (estrogen receptor, progesterone receptor, and HER2‐negative) breast cancer and HER2‐positive breast cancer. How computational assessments of TILs might complement manual TIL assessment in trial and daily practices is currently debated. Recent efforts to use machine learning (ML) to automatically evaluate TILs have shown promising results. We review state‐of‐the‐art approaches and identify pitfalls and challenges of automated TIL evaluation by studying the root cause of ML discordances in comparison to manual TIL quantification. We categorize our findings into four main topics: (1) technical slide issues, (2) ML and image analysis aspects, (3) data challenges, and (4) validation issues. The main reason for discordant assessments is the inclusion of false‐positive areas or cells identified by performance on certain tissue patterns or design choices in the computational implementation. To aid the adoption of ML for TIL assessment, we provide an in‐depth discussion of ML and image analysis, including validation issues that need to be considered before reliable computational reporting of TILs can be incorporated into the trial and routine clinical management of patients with triple‐negative breast cancer. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
- 23 August 2023
- Published by Wiley in The Journal of Pathology
- Vol. 260 (5) , 498-513
Open AccessPitfalls in machine learning‐based assessment of tumor‐infiltrating lymphocytes in breast cancer: A report of the International Immuno‐Oncology Biomarker Working Group on Breast Cancer
The clinical significance of the tumor‐immune interaction in breast cancer is now established, and tumor‐infiltrating lymphocytes (TILs) have emerged as predictive and prognostic biomarkers for patients with triple‐negative (estrogen receptor, progesterone receptor, and HER2‐negative) breast cancer and HER2‐positive breast cancer. How computational assessments of TILs might complement manual TIL assessment in trial and daily practices is currently debated. Recent efforts to use machine learning (ML) to automatically evaluate TILs have shown promising results. We review state‐of‐the‐art approaches and identify pitfalls and challenges of automated TIL evaluation by studying the root cause of ML discordances in comparison to manual TIL quantification. We categorize our findings into four main topics: (1) technical slide issues, (2) ML and image analysis aspects, (3) data challenges, and (4) validation issues. The main reason for discordant assessments is the inclusion of false‐positive areas or cells identified by performance on certain tissue patterns or design choices in the computational implementation. To aid the adoption of ML for TIL assessment, we provide an in‐depth discussion of ML and image analysis, including validation issues that need to be considered before reliable computational reporting of TILs can be incorporated into the trial and routine clinical management of patients with triple‐negative breast cancer. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
- 25 July 2023
- Published by Hospital Universitário Getulio Vargas in Revista do Hospital Universitário Getúlio Vargas
- Vol. 22 (1) , 1-9
Ética do uso de cadáveres humanos para ensino de anatomia
O ensino da anatomia através da dissecção de cadáveres humanos foi, por séculos, a base pedagógica fundamental para a formação de médicos e outros profissionais de saúde. No entanto, apesar de a prática acompanhar a história da medicina desde seus primórdios, até o presente momento não há, na formação do médico, um foco adequado sobre os aspectos éticos relacionados à realização desse procedimento. Tais questões são complexas e envolvem desde a obtenção do cadáver, seu método de preservação, manuseio diário e posterior descarte adequado. Porém, a questão ética central a ser debatida é se a pessoa cujo corpo será fonte para atividades apresentou consentimento para tal. O presente trabalho tem por finalidade realizar breve revisão da história da dissecção humana, os princípios éticos que cercam o tema, seus potenciais conflitos e aspectos legais sobre a utilização de cadáveres para a formação do profissional de saúde.
- 25 July 2023
- Published by Hospital Universitário Getulio Vargas in Revista do Hospital Universitário Getúlio Vargas
- Vol. 22 (1) , 1-9
Ética do uso de cadáveres humanos para ensino de anatomia
O ensino da anatomia através da dissecção de cadáveres humanos foi, por séculos, a base pedagógica fundamental para a formação de médicos e outros profissionais de saúde. No entanto, apesar de a prática acompanhar a história da medicina desde seus primórdios, até o presente momento não há, na formação do médico, um foco adequado sobre os aspectos éticos relacionados à realização desse procedimento. Tais questões são complexas e envolvem desde a obtenção do cadáver, seu método de preservação, manuseio diário e posterior descarte adequado. Porém, a questão ética central a ser debatida é se a pessoa cujo corpo será fonte para atividades apresentou consentimento para tal. O presente trabalho tem por finalidade realizar breve revisão da história da dissecção humana, os princípios éticos que cercam o tema, seus potenciais conflitos e aspectos legais sobre a utilização de cadáveres para a formação do profissional de saúde.
- Open Access
- 1 April 2012
- Published by Elsevier in Cirugía Cardiovascular
- Vol. 19 (2) , 194
245. Resultados de la implementación de un programa de cirugía mínimamente invasiva para cardiopatías congénitas-estructurales
- 1 April 2012
- Published by Elsevier in Cirugía Cardiovascular
- Vol. 19 (2) , 194
Open Access245. Resultados de la implementación de un programa de cirugía mínimamente invasiva para cardiopatías congénitas-estructurales